Dr. Hyojeong C. Han

AeRang Kim, MD, PhD, is a member of the solid tumor faculty at Children’s National Hospital and an Associate Professor of Pediatrics. Dr. Kim's specializes in sarcomas and developmental therapeutics. Her research focuses on development of novel therapeutics for pediatric cancer including pre-clinical testing of novel agents, pharmacokinetic analysis, developing innovative methods for toxicity monitoring and clinical trial design. She serves as the principal investigator of multiple early phase trials in pediatric oncology, sarcomas and NF1 associated tumors. Dr. Kim is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1 (NF1), Neurofibromatosis, and Adult Soft Tissue Sarcoma. Dr. Kim is board certified in Pediatrics: American Board Of Pediatrics, 2004 and Pediatric Hematology-Oncology: American Board Of Pediatrics, 2009.

Jeffrey Dome, MD, PhD, is senior vice president of the Cancer and Blood Disorders Center at Children’s National Hospital in Washington, D.C. He is professor of pediatrics at the George Washington University School of Medicine and Health Sciences and the Thomas Willson and Lenore Williams McKnew professor of pediatric oncology. Dr. Dome received his medical degree from the University of Pennsylvania School of Medicine and PhD degree in medicine from Erasmus University in Rotterdam. He completed a residency in pediatrics at Yale-New Haven Hospital and completed a fellowship in pediatric hematology/oncology at Johns Hopkins Hospital. After fellowship, Dr. Dome was a faculty member at St. Jude Children’s Research Hospital before joining Children’s National in 2006. Dr. Dome is an internationally recognized expert on pediatric solid tumors, with an emphasis on kidney tumors and sarcomas. He chaired the Children’s Oncology Group (COG) Renal Tumor Committee for more than a decade. He is presently on the Scientific Council of the COG, the editorial board of Pediatric Blood and Cancer, and is past chair of the American Board of Pediatrics Subboard of Hematology/Oncology. Dr. Dome serves on numerous medical advisory boards for cancer foundations and currently is the North American Continental President of the International Society of Pediatric Oncology (SIOP). He has authored more than 200 articles, books, letters and chapters on pediatric cancer. Dr. Dome is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Rhabdoid Tumor, Denys-Drash Syndrome (DDS), Adult Soft Tissue Sarcoma, Nephrectomy, and Bone Marrow Aspiration. Dr. Dome is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 1998.

Meghan Delaney, DO, MPH, is the chief of the Division of Pathology and Lab Medicine and director of Transfusion Medicine. She is the professor of Pathology and Pediatrics and the George Washington University. Dr. Delaney serves as a member of the Board of Directors for the Association for the Advancement of Blood & Biotherapies (AABB), a scientific member of the BEST Collaborative and member of the American Board of Pathology Test Development and Advisory Committee. Dr. Delaney’s scholarly focus is in clinical pathology, laboratory management, transfusion medicine, pediatric transfusion medicine and immunohematology. She has over 100 peer reviewed publications and lectures nationally and internationally. In global health, Dr. Delaney focuses on improving access to safe blood transfusion in developing nations. She serves as the Chair of NIH’s BLOODSAFE Program that aims to improve access to safe blood in Sub Saharan Africa. The British Blood Transfusion Society (BBTS) recognized Dr. Delaney with the 2021 James Blundell Award. This is the most prestigious award given by the BBTS. Introduced in 1984, this award is given to recipients for original research resulting in an important and significant contribution to the body of medical and or scientific knowledge within the field of blood transfusion. Dr. Delaney is highly rated in 3 conditions, according to our data. Her clinical expertise encompasses Hemolytic Disease of the Newborn, Anemia, Multisystem Inflammatory Syndrome in Children (MIS-C), and Kawasaki Disease. Dr. Delaney is board certified in Blood Banking/Transfusion Medicine: American Board Of Pathology, 2008 and Clinical Pathology: American Board Of Pathology, 2007.